GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (NAS:OPGN) » Definitions » EPS without NRI

OpGen (OPGN) EPS without NRI : $-4.51 (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OpGen EPS without NRI?

OpGen's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.45. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-4.51.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 57.70% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 70.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for OpGen's EPS without NRI or its related term are showing as below:

OPGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 7   Med: 59.6   Max: 80
Current: 57.7

During the past 10 years, OpGen's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 80.00% per year. The lowest was 7.00% per year. And the median was 59.60% per year.

OPGN's 3-Year EPS without NRI Growth Rate is ranked better than
90% of 700 companies
in the Medical Devices & Instruments industry
Industry Median: 9.65 vs OPGN: 57.70

OpGen's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.46. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.51.

OpGen's EPS (Basic) for the three months ended in Sep. 2023 was $-0.46. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-6.51.


OpGen EPS without NRI Historical Data

The historical data trend for OpGen's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen EPS without NRI Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -889.66 -137.95 -31.58 -20.14 -10.42

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.98 -1.91 -1.23 -0.93 -0.45

Competitive Comparison of OpGen's EPS without NRI

For the Medical Devices subindustry, OpGen's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where OpGen's PE Ratio without NRI falls into.



OpGen EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OpGen  (NAS:OPGN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


OpGen EPS without NRI Related Terms

Thank you for viewing the detailed overview of OpGen's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (OPGN) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Executives
Yvonne Schlaeppi director 600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893
Johannes Bacher officer: Chief Operating Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Albert Weber officer: Chief Finanical Officer MARIENBURGER STR. 7, BERLIN 2M 10405
Oliver Schacht director, officer: Chief Executive Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Evan/ Fa Jones director, officer: Chief Executive Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
William E. Rhodes director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Curetis N.v. In Liquidation 10 percent owner MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088
Mario Crovetto director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Vadim M. Sapiro officer: Chief Information Officer C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Timothy C Dec officer: Chief Financial Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Jven Capital, Llc 10 percent owner P.O. BOX 60207, POTOMAC MD 20859
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Harry J D'andrea director 6480 DOBBIN ROAD, COLUMBIA MD 21045